Analysis of Clinical Efficacy and Safety of Ustekinumab in Treatment of Inflammatory Bowel Disease / 胃肠病学
Chinese Journal of Gastroenterology
; (12): 711-716, 2022.
Article
in Zh
| WPRIM
| ID: wpr-1016056
Responsible library:
WPRO
ABSTRACT
Background:
The efficacy of ustekinumab (UST) in the treatment of patients with inflammatory bowel disease (IBD) has been affirmed abroad, but its efficacy and safety have not been reported in China due to its short term of use.Aims:
To analyze the clinical efficacy and safety of UST in the treatment of IBD.Methods:
The clinical data of IBD patients treated with UST from November 2020 to June 2022 in the First Affiliated Hospital of Air Force Medical University were analyzed retrospectively.Results:
A total of 46 patients with IBD treated with UST were enrolled, including 41 patients with Crohn’s disease (CD) and 5 patients with ulcerative colitis (UC). At the 8
Full text:
1
Database:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Gastroenterology
Year:
2022
Document type:
Article